Application of union of benzisoselenazolone derivative and metabolism resistant medicine to preparation of medicines for treating tumors

Abstract

The invention belongs to the technical field of tumor treatment, and discloses an application of the union of a benzisoselenazolone derivative and a metabolism resistant medicine to preparation of medicines for treating tumors. The benzisoselenazolone derivative has a structure of a compound as shown in a formula A. The metabolism resistant medicine is selected from one or more of a pyrimidine antagonist, a purine antagonist and a folic acid antagonist. The molar ratio of the benzisoselenazolone derivative to the metabolism resistant medicine is (1-10) to (1-10). The inventor of the inventionfinds that united application of BS and the metabolism resistant medicine (particularly 5-FU) has excellent synergistic inhibition effects on tumor cell proliferation, particularly obvious inhibitioneffects on liver cancer cell proliferation, and has great value on tumor treatment beyond all expectation.

Description

technical field [0001] The invention belongs to the technical field of tumor treatment, and specifically relates to the application of a benzisoselenazole derivative combined with an anti-metabolite drug in the preparation of a drug for treating tumors. Background technique [0002] Primary hepatocellular carcinoma (hereafter referred to as liver cancer) is one of the most common malignant tumors in humans. According to reports, the incidence of liver cancer ranks sixth among all malignant tumors in the world, while the mortality rate ranks third. In my country, about 383,000 people die of liver cancer every year, accounting for 51% of the global liver cancer deaths, which seriously threatens human life and health. [0003] Due to the rapid proliferation of liver cancer cells, it is difficult to diagnose in the early stage. When liver cancer is diagnosed, most patients have already developed to the advanced stage of liver cancer, and often accompanied by intrahepatic or ext...

AI Technical Summary

Problems solved by technology

However, anti-metabolite drugs generally have bone marrow toxicity in the second week after administration, often manifested as leukopenia and thrombocytopenia. cancer less effective

Images